Search Results for “immune” – Page 5 – media

People with Long COVID neurological symptoms found to have differences in immune cell profiles and autonomic dysfunction

Twelve people with persistent neurological symptoms after SARS-CoV-2 infection were intensely studied at the National Institutes of Health (NIH) and were found to have differences in their immune cell profiles and autonomic dysfunction. These data inform future studies to help explain persistent neurological symptoms in Long COVID. The findings, published in Neurology: Neuroimmunology & Neuroinflammation, may lead to better diagnoses and new treatments. People with post-acute sequelae of COVID-19 (PASC), which includes Long COVID, have a wide range of symptoms, including fatigue, shortness of breath, fever, headaches, sleep disturbances, and “brain fog,” or cognitive impairment. Such symptoms can last for months or longer after an initial SARS-CoV-2 infection. Fatigue and “brain fog” are among the most common and debilitating symptoms, and likely stem from nervous system dysfunction. Researchers used an approach called deep phenotyping to closely examine the clinical and biological features of Long COVID in 12 people who ...
- Source: drugdu
- 238
- May 8, 2023
NIH researchers gain new insights on rare immune deficiency

In an 11-year study, researchers at the National Institutes of Health have further characterized idiopathic CD4 lymphocytopenia (ICL), a rare immune deficiency that leaves people vulnerable to infectious diseases, autoimmune diseases and cancers. Researchers observed that people with the most severe cases of ICL had the highest risk of acquiring or developing several of the diseases associated with this immune deficiency. This study, published in the New England Journal of Medicine, was led by Irini Sereti M.D., M.H.S. and Andrea Lisco, M.D., Ph.D. of the HIV Pathogenesis Section in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious diseases (NIAID), part of NIH, and conducted at the NIH Clinical Center. ICL is a condition marked by too few CD4+ T-cells, which are a type of white blood cell. The clinical definition of ICL is a CD4+ T-cell count of less than 300 cells per cubic ...
- Source: drugdu
- 161
- May 6, 2023
Apellis’ immune system drug hits a setback in ALS

Jacob Bell Senior Reporter In the latest setback for ALS research, Apellis Pharmaceuticals, a Massachusetts-based drug company, has discontinued a portion of a key clinical trial testing one of its medicines as a treatment for the nerve-destroying disease. The “MERIDIAN” trial began in the fall of 2020, ultimately enrolling around 250 participants who were given either a placebo or Apellis’ medicine, known as pegcetacoplan, over a two-year period. Following that period, participants could join a so-called “open-label extension” study, in which everyone would have access to the drug. But Apellis has chosen to stop that latter study, based on feedback from an external group of advisers who reviewed the data available and concluded further treatment with the drug was unwarranted. Analysts at the investment bank Mizuho Securities were the first to report this development. According to the analyst Graig Suvannavejh, Apellis announced the study discontinuation through a “company communication” that clarified that the ...
- Source: drugdu
- 166
- April 25, 2023
Pregnant women show unique immune response to COVID-19

Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, has claimed more than 6.8 million lives worldwide. It remains imperative to understand the immune responses to SARS-CoV-2, particularly in high-risk groups, to formulate better vaccination and treatment strategies. The immune response to COVID-19 during pregnancy Immunological assessment related to COVID-19 has been performed largely in healthy individuals across varied age groups. After contracting SARS-CoV-2 infection, patients typically develop robust and transient immune responses that include an abundance of SARS-CoV-2-specific antibodies, T-cells, B-cells, and long-lasting immune memory. Severe SARS-CoV-2 infection has been characterized by the presence of blood hypercytokinemia and hyperactivation of innate/adaptive immune responses. Limited studies have been performed on the immune response after SARS-CoV-2 infection in pregnant women. Pregnant women are considered to be highly susceptible to COVID-19 due to immunological and physiological changes ...
- Source: drugdu
- 114
- April 17, 2023
ImmuneBridge raises funds to advance new cell-based immunotherapies

Biotechnology company ImmuneBridge has raised $12m seed financing to advance new natural killer (NK) cell-based immunotherapies. Co-led by global investors Insight Partners and M Ventures, the financing round has also seen participation from Gaingels and One Way Ventures. ImmuneBridge is developing allogeneic NK cell-based immunotherapies to treat solid tumours and hematologic malignancies. According to the company, NK cells represent a platform for allogeneic immunotherapy as they are potent cancer killers, with less risk profile. The company’s orthogonal approach leverages an expansion technology and a diverse clinic-ready source for accelerating the discovery and translation of potent cell therapies. Its expansion technology expands hematopoietic stem cells (HSCs), which are natural NK cells precursors. ImmuneBridge CEO and co-founder Peretz Partensky said: “Cell therapy is a new pillar of medicine and is inextricably human. Cell therapy developers fear donor-to-donor variability, yet we humans are unapologetically diverse in our innate ...
- Source: drugdu
- 114
- April 13, 2023
GSK outlines deal to send cell therapies back to Adaptimmune

The pharma is handing back two experimental cancer medicines amid a retreat from cell therapy research. GSK has outlined a deal to send two cancer immunotherapies back to biotechnology company Adaptimmune Therapeutics, a move that follows the larger drugmaker’s recent decision to stop investing in cell and gene therapy research. Adaptimmune announced last October that it would regain rights to the two programs, each of which are in development for solid tumors. On Tuesday, the biotech revealed terms of the agreement. It will get about $37 million in cash from GSK, and receive all materials, data and trial sponsorship responsibilities related to the drugs later this year. The agreement will formally end a partnership between GSK and Adaptimmune that dates back to 2014. That year, the two began working on a program called lete-cel, which works by genetically modifying cells to detect NY-ESO, a protein expressed on several ...
- Source: drugdu
- 262
- April 12, 2023
SARS-CoV-2 infection weakens immune-cell response to vaccination

Colorized scanning electron micrograph of a cell (red) infected with the Omicron strain of SARS-CoV-2 virus particles (blue), isolated from a patient sample.NIAID The magnitude and quality of a key immune cell’s response to vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, a study has found. In addition, the level of this key immune cell that targets the SARS-CoV-2 spike protein was substantially lower in unvaccinated people with COVID-19 than in vaccinated people who had never been infected. Importantly, people who recover from SARS-CoV-2 infection and then get vaccinated are more protected than people who are unvaccinated. These findings, which suggest that the virus damages an important immune-cell response, were published today in the journal Immunity. The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National ...
- Source: drugdu
- 129
- April 6, 2023
Early data shows CanSinoBIO’s inhaled COVID-19 vaccine triggers immune response

CanSinoBIO’s inhaled COVID-19 vaccine candidate was found to trigger immune responses with no serious side effects reported, according to an early-stage clinical study. The inhaled two-dose candidate is modified from CanSinoBIO’s injected COVID-19 jab Ad5-nCoV vaccine, which is already approved in China and other countries around the world. Results from a Phase I clinical trial, published in The Lancet, found that two-doses of the inhaled Ad5-nCoV vaccine can trigger a similar immune response to a single-dose of the injected version. The inhaled version was also found to trigger neutralising antibodies and T cell responses after one dose. The study also found that the inhaled version of the vaccine did not cause serious side effects, demonstrating an encouraging safety profile in the early-stage trial. A number of drugmakers are also developing inhaled treatments for COVID-19, including Verona Pharma. UK-headquartered Verona announced at the beginning of the year that it had completed enrolment ...
- Source: drugdu
- 972
- September 1, 2021
CanSinoBIO
Aimmune’s peanut allergy med Palforzia wins EU approval

The European Commission (EC) has approved Aimmune Therapeutics’ Palforzia, making it the first treatment for peanut allergy in the EU, according to the firm. Following the EC approval, Palforzia will be available to patients aged four to 17 years with a confirmed diagnosis of peanut allergy. It is not, however, indicated for the treatment of allergic reactions – including anaphylaxis – and must be used in conjunction with a peanut-avoidant diet. The drug can also be continued in patients aged 18 years or older, Aimmune added in a statement. The EC approval was based on a data package including two phase III clinical trials – PALISADE and ARTEMIS. Across both studies, Palforzia treatment led to a significant increase in the amount of peanut protein tolerated in participants with peanut allergy, compared to placebo. “Today’s approval is a historic moment for the millions of people living with potentially life-threatening peanut allergy, ...
- Source: drugdu
- 356
- December 22, 2020
Peanut allergy
Blocking Immune System Pathway Could Stop COVID-19 Infection, Finds Study

By HospiMedica International staff writers Posted on 14 Oct 2020 Image: Colorized scanning electron micrograph of a cell (purple) heavily infected with SARS-CoV-2 virus particles (yellow) (Photo courtesy of National Institute of Allergy and Infectious Diseases, National Institutes of Health) A recent study has shown that blocking a specific protein in a biological pathway may prevent SARS-CoV-2 infection and keep the virus from misdirecting the immune system against healthy cells and organs. While the world waits eagerly for a safe and effective vaccine to prevent infections from SARS-CoV-2, the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact. The key to one possibility – blocking a protein that enables the virus to turn the immune system against healthy cells – has been identified in a recent study by ...
- Source: drugdu
- 301
- October 15, 2020

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.